Shane Arsenault, MD, Memorial University of Newfoundland, St. John’s, Canada, discusses future work on multiple sclerosis (MS) biomarkers and their impact on clinical practice. Various studies have investigated potential MS biomarkers in the CSF; however, this requires the patient to undergo lumbar punctures. While lumbar punctures for CSF collection are generally considered safe procedures, they constitute a significant barrier for more widespread use. Therefore, future studies will focus on measuring biomarkers in the serum or plasma. Additionally, Dr Arsenault’s project looks at serum or plasma neurofilament light chain (NfL) levels in patients with relapsing-remitting MS and how they are explicitly impacted by different disease-modifying treatment (DMT) subtypes. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.